EMEA-000016-PIP01-07-M07

Key facts

Invented name
Xydalba
Active substance
Dalbavancin
Therapeutic area
Infectious diseases
Decision number
P/0377/2019
PIP number
EMEA-000016-PIP01-07-M07
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of acute bacterial skin and skin structure infections
Route(s) of administration
Intravenous use
Contact for public enquiries
Allergan Pharmaceuticals International Limited

E-mail: ml-eu_reg_affairs@allergan.com
Tel. +44 (0)1628 4944444

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating